Medicare does not cover Wegovy, and current rules make coverage unlikely in the near term
Medicare Part D (prescription drug coverage) explicitly excludes weight-loss drugs, including Wegovy (semaglutide). This exclusion has been in place for decades and applies to all Medicare beneficiaries, regardless of which Part D plan they choose. Even if your plan covers other injectable medications, Wegovy will not be among them.
The ban exists because Medicare law treats weight-loss drugs as cosmetic rather than medically necessary. However, the landscape is shifting. In 2023 and 2024, some private insurers began covering Wegovy and similar drugs (like Ozempic when used for weight loss) for patients with obesity and related health conditions. Medicare has not followed, but the conversation inside the agency has started.
If you are a Medicare beneficiary paying out of pocket for Wegovy, you have limited options to reduce the cost. This article explains what Medicare does and does not cover, what may change, and what you can do now.
Key Takeaways
- Medicare Part D plans are prohibited by federal law from covering weight-loss drugs like Wegovy, and this applies to all Medicare beneficiaries without exception.
- The exclusion is based on Medicare's classification of weight-loss drugs as cosmetic, not medically necessary, even when prescribed for obesity-related conditions.
- Some private insurers have begun covering Wegovy for patients with obesity and related health problems, but Medicare has not changed its rules.
- If you are on Medicare and taking Wegovy, you may reduce costs through the manufacturer's savings program, but you cannot use Medicare to pay for the drug itself.
- Changes to Medicare coverage would require action by Congress or a formal change to Medicare's benefit rules, neither of which is imminent.
Why Medicare excludes weight-loss drugs
The exclusion is written into the Medicare statute itself. When Congress created Medicare Part D in 2003, it included a specific prohibition: Medicare cannot pay for drugs "used for weight loss or weight management." This language has remained unchanged.
The reasoning behind the ban reflects an older medical consensus that weight loss was primarily a lifestyle issue, not a disease requiring pharmaceutical treatment. Obesity was not classified as a disease by Medicare until 2013, but the drug exclusion remained in place even after that reclassification. The statute would need to be amended by Congress to remove the ban.
This means that even if your doctor prescribes Wegovy for a weight-related condition — such as type 2 diabetes, heart disease, or high blood pressure — Medicare will not cover it. The medical reason for the prescription does not override the statutory exclusion.
What private insurers are doing differently
Beginning in 2023, some private health insurers started covering GLP-1 receptor agonists (the drug class that includes Wegovy) for weight management in patients with obesity and related conditions. Insurers such as UnitedHealthcare, Aetna, and Cigna have added coverage, usually with restrictions: the patient must have a BMI above a certain threshold, documented weight-related health conditions, and proof of prior attempts at diet and exercise.
These private plans are not bound by Medicare's statutory exclusion. They can make their own coverage decisions based on clinical evidence and cost-benefit analysis. The shift reflects growing medical consensus that GLP-1 drugs are effective for weight loss and can reduce the risk of heart attack and stroke in people with obesity and cardiovascular disease.
Medicare Advantage plans (Part C) are also private insurers, but they must follow Medicare's rules on covered benefits. Even though a Medicare Advantage plan might cover other drugs generously, it cannot cover Wegovy because Medicare itself prohibits it.
The current cost of Wegovy without insurance
Wegovy costs approximately $900 to $1,350 per month at retail pharmacy prices, depending on the dose and location. Most people take it for several months or longer, making the total cost substantial.
Novo Nordisk, the manufacturer, offers a savings program called Wegovy Savings Card. If you are uninsured or your insurance does not cover the drug, the card can reduce your out-of-pocket cost to as low as $99 per month for up to 24 months. You must meet income requirements (generally under $55,000 for an individual or $110,000 for a family of four, though these limits vary). The program is available to Medicare beneficiaries.
Some community health centers and state pharmaceutical information programs also offer reduced-cost medications, though availability varies by location. Your doctor's office may have information about local resources.
Could Medicare coverage change?
Change is possible but not imminent. Several factors would need to align:
- Congress would need to amend the Medicare statute to remove or modify the weight-loss drug exclusion. This requires legislative action and has not been introduced as a priority bill.
- The Centers for Medicare & Medicaid Services (CMS) could issue new guidance interpreting the exclusion more narrowly — for example, covering Wegovy only when prescribed for a specific condition like cardiovascular disease prevention. This is less likely than statutory change but does not require Congress.
- Continued evidence that GLP-1 drugs reduce heart attacks and strokes in people with obesity could shift the medical and political conversation, making coverage a higher priority.
As of early 2024, neither Congress nor CMS has signaled imminent action. The exclusion remains in effect for all Medicare beneficiaries.
What to do if you are on Medicare and want Wegovy
If your doctor has prescribed Wegovy and you are on Medicare, here are your options:
- Use the manufacturer's savings card. Contact Novo Nordisk or ask your pharmacy about the Wegovy Savings Card. You will need to verify your income and insurance status. This is the fastest way to reduce cost.
- Check your state's pharmaceutical information program. Some states offer reduced-cost medications for residents who meet income requirements. Your state health department or your doctor's office can direct you to the program.
- Ask your doctor about alternatives. Older weight-loss medications like phentermine are sometimes covered by Medicare Part D, though they are less effective than Wegovy. Your doctor can discuss whether an alternative makes sense for your situation.
- Review your Medicare Advantage plan's coverage of other medications. If you are on Medicare Advantage, check whether your plan covers other GLP-1 drugs (such as Ozempic for diabetes). Coverage varies by plan, and some plans may cover a GLP-1 for diabetes that could be used off-label for weight loss — though this is not standard practice.
Frequently Asked Questions
Can I use my Medicare Advantage plan to pay for Wegovy?
No. Medicare Advantage plans must follow Medicare's rules on covered benefits. Even though a Medicare Advantage plan might cover other drugs, it cannot cover Wegovy because Medicare itself prohibits coverage of weight-loss drugs. The exclusion applies to all Medicare beneficiaries, regardless of plan type.
What if my doctor says Wegovy is medically necessary for my diabetes or heart condition?
Medicare's exclusion applies regardless of the medical reason for the prescription. Even if your doctor documents that Wegovy is necessary to treat a weight-related condition, Medicare will not cover it. The statutory ban on weight-loss drugs overrides individual medical judgments. Your doctor can help you find other resources, such as the manufacturer's savings program.
Will Medicare cover Wegovy if I have obesity and another condition like heart disease?
Not under current rules. Medicare does not distinguish between weight loss for cosmetic reasons and weight loss for medical reasons. The exclusion is absolute. However, if new evidence emerges that Wegovy prevents heart attacks or strokes, Congress or CMS could revisit the rule — but this has not happened yet.
Are there other weight-loss drugs that Medicare does cover?
Medicare Part D may cover older weight-loss medications such as phentermine, though coverage depends on your specific plan. These drugs are less effective than Wegovy and are typically prescribed for short-term use only. Ask your doctor or your plan whether older weight-loss medications are covered under your Part D plan.
How long does the manufacturer's savings card last?
The Wegovy Savings Card typically covers up to 24 months of treatment at a reduced cost (often $99 per month). After 24 months, you would need to pay full price or find another information program. Ask the program administrator about what happens when the 24-month period ends.